Robert Anderson
Family Medicine · Penn Yan, NYNPI 1255586400
Payments from drug & device makers
Across 797 payments — averaging $18.04 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AstraZeneca$2K
- Novo Nordisk$2K
- Pfizer$1K
- Boehringer Ingelheim$1K
- Lilly USA, LLC$979
- GSK$921
- plus $6K from 39 others
What the payments were for
- Food & beverage$14,367100%
- Education$120%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$14,378 in reported general payments places this provider in the 95th percentile of 4,321 family medicine providers in New York.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OzempicSemaglutide | 139 | $274,478 |
| TrulicityDulaglutide | 127 | $272,520 |
| EliquisApixaban | 220 | $269,298 |
| Synjardy XrEmpagliflozin/Metformin Hcl | 124 | $167,071 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 164 | $126,127 |
| JardianceEmpagliflozin | 89 | $122,030 |
| FarxigaDapagliflozin Propanediol | 74 | $104,121 |
| Xigduo XrDapaglifloz Propaned/Metformin | 74 | $95,870 |
| XareltoRivaroxaban | 67 | $90,082 |
| SynjardyEmpagliflozin/Metformin Hcl | 47 | $60,263 |
| RybelsusSemaglutide | 32 | $57,519 |
| KerendiaFinerenone | 28 | $50,061 |
| Breztri AerosphereBudesonide/Glycopyr/Formoterol | 39 | $39,468 |
| Toujeo Max SolostarInsulin Glargine,hum.Rec.Anlog | 32 | $35,050 |
| ProliaDenosumab | 16 | $26,015 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Boehringer IngelheimSynjardy Xr, Jardiance, Synjardy, Stiolto Respimat | $1,125 | $361,110274 claims |
| Novo NordiskOzempic, Rybelsus | $1,898 | $331,996171 claims |
| Lilly USA, LLCTrulicity, Mounjaro | $979 | $286,709141 claims |
| PfizerEliquis, Paxlovid | $1,395 | $277,574241 claims |
| GSKTrelegy Ellipta, Anoro Ellipta, Breo Ellipta, Incruse Ellipta | $921 | $157,190227 claims |
| AstraZenecaFarxiga, Breztri Aerosphere | $1,994 | $143,590113 claims |
| Johnson & JohnsonXarelto, Invokana | $236 | $115,00583 claims |
| BayerKerendia | $534 | $50,06128 claims |
| AmgenProlia | $827 | $26,01516 claims |
| Astellas Pharma US IncMyrbetriq | $279 | $22,66129 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 4,321 family medicine providers in New York.
Other family medicine in Penn Yan
- Matthew DavisRochester$76.6M
- Frank EderBinghamton$46.2M
- Suchet PatelEndwell$23.3M
- James WildGowanda$2.2M
- Michael FedericoEndwell$1.4M
- Donald BrautigamWestfield$1.3M
- Kimberly DesantisEndwell$1.1M
- Michael TugetmanHartsdale$1M
- Richard RuhOrchard Park$769K
- Eric LorraineEndwell$740K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.